CN106605818B - Instant granule of Shangqingyin and its preparation method - Google Patents
Instant granule of Shangqingyin and its preparation method Download PDFInfo
- Publication number
- CN106605818B CN106605818B CN201611149253.0A CN201611149253A CN106605818B CN 106605818 B CN106605818 B CN 106605818B CN 201611149253 A CN201611149253 A CN 201611149253A CN 106605818 B CN106605818 B CN 106605818B
- Authority
- CN
- China
- Prior art keywords
- supernatant
- parts
- ethanol
- supernatant fluid
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 67
- 239000006228 supernatant Substances 0.000 claims abstract description 43
- 235000011517 Terminalia chebula Nutrition 0.000 claims abstract description 20
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 19
- 244000277583 Terminalia catappa Species 0.000 claims abstract description 18
- 235000013361 beverage Nutrition 0.000 claims abstract description 18
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 12
- 235000011477 liquorice Nutrition 0.000 claims abstract description 12
- 235000014676 Phragmites communis Nutrition 0.000 claims abstract description 10
- 244000215777 Plumeria rubra Species 0.000 claims abstract description 9
- 235000013087 Plumeria rubra Nutrition 0.000 claims abstract description 9
- 240000002505 Pogostemon cablin Species 0.000 claims abstract description 9
- 235000011751 Pogostemon cablin Nutrition 0.000 claims abstract description 9
- 241001646828 Platostoma chinense Species 0.000 claims abstract description 8
- 238000007670 refining Methods 0.000 claims abstract description 7
- 239000011347 resin Substances 0.000 claims abstract description 7
- 229920005989 resin Polymers 0.000 claims abstract description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 238000005406 washing Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- 239000001116 FEMA 4028 Substances 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 10
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 10
- 229960004853 betadex Drugs 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 9
- 239000000811 xylitol Substances 0.000 claims description 9
- 235000010447 xylitol Nutrition 0.000 claims description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 9
- 229960002675 xylitol Drugs 0.000 claims description 9
- 108010011485 Aspartame Proteins 0.000 claims description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims description 8
- 229960005070 ascorbic acid Drugs 0.000 claims description 8
- 239000011668 ascorbic acid Substances 0.000 claims description 8
- 235000010357 aspartame Nutrition 0.000 claims description 8
- 239000000605 aspartame Substances 0.000 claims description 8
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 8
- 229960003438 aspartame Drugs 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 238000005550 wet granulation Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 abstract description 19
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 5
- 238000005457 optimization Methods 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 238000001556 precipitation Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 238000003809 water extraction Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 32
- 241000700159 Rattus Species 0.000 description 17
- 230000008961 swelling Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 210000003371 toe Anatomy 0.000 description 13
- 240000001624 Espostoa lanata Species 0.000 description 12
- 235000009161 Espostoa lanata Nutrition 0.000 description 12
- 206010018691 Granuloma Diseases 0.000 description 9
- 239000003381 stabilizer Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000001522 Terminalia chebula Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 2
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000015092 herbal tea Nutrition 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 240000004510 Agastache rugosa Species 0.000 description 1
- 206010003800 Auricular swelling Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000270923 Hesperostipa comata Species 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 241001646834 Mesona Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000009330 Terminalia Nutrition 0.000 description 1
- 241001534869 Terminalia Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000510764 Villosa Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/72—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter by filtration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/80—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter by adsorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a supernatant fluid instant granule and a preparation method thereof, the supernatant fluid instant granule is prepared from a supernatant fluid extract and pharmaceutically acceptable auxiliary materials, the supernatant fluid extract is prepared from myrobalan, frangipani, mesona chinensis benth, fresh reed rhizome, pogostemon cablin and liquorice through water extraction and alcohol precipitation, macroporous resin purification and refining and micronization, and the supernatant fluid instant granule obtained through formula optimization has better anti-inflammatory and health-care effects compared with the traditional decoction and low sugar fluid beverage, and is obviously improved in the aspects of solubility, brewing condition and the like. Has good taste, and is convenient for carrying, administration and storage.
Description
Technical Field
The invention relates to supernatant beverage instant granules and a preparation method thereof, belonging to the field of food processing.
Background
The herbal tea is a general name for beverage which is developed and summarized by Lingnan people according to local climate, water and soil characteristics, the traditional Chinese medicine health preserving theory as guidance in the process of long-term disease prevention and health care and the Chinese herbal medicine as basis and has the effects of clearing heat and removing toxicity, promoting the production of body fluid and quenching thirst and the like.
According to the findings of researchers in Shaanxi province, the Tang dynasty era China popularizes a myrobalan soup beverage which is prepared by drawing and decocting fresh myrobalan and liquorice in water, has fragrant and slightly sweet taste, clears heat and quenches thirst and is also called myrobalan spring.
The myrobalan spring originates from Guangzhou and is sent to the temple. A well is arranged in the ancient temple, well water is cool and mellow, and is very effective on throat and dryness-heat diseases, and the reason that the myrobalan fruit 'myrobalan' beside the well falls into the well is mainly found in the temple of drinkers. Lingnan foreign body note is a record: when there is a good guest in each son, the Homing monk (the temple of Guangxi) should be decocted for a prolonged time. Five newly picked myrobalans, one inch of liquorice, ground breaking, well sucking and water decocting together, the color is like that of a new tea, the south sea popular and honor soup, and the doctor contend for drinking.
The herbal tea for the supernatant fluid is derived from myrobalan spring, is based on myrobalan which is gradually formed through the research of famous physicians, and combines the faint scent and sweetness of the myrobalan, reed rhizome, wrinkled gianthyssop herb, liquorice and other herbs with beautiful color, smell and taste, is natural and pure, and can be used for daily drinking for clearing heat and promoting the secretion of saliva or body fluid.
The fructus Chebulae contained in the supernatant is dried mature fruit of Terminalia chebula Retz or Terminalia villosa Retz, and is distributed in Yunnan province. Bitter, sour and astringent in flavor, neutral in nature, entering lung and large intestine meridians. Has the effects of astringing intestines to check diarrhea, astringing lung to relieve cough, reducing pathogenic fire and relieving sore throat. It is commonly indicated for cough and dyspnea due to lung deficiency, chronic cough, pharyngalgia, hoarseness, etc.
At present, the supernatant drink is mostly traditional decoction or low-sugar concentrate, and no report is provided on the supernatant drink instant product.
Disclosure of Invention
The invention aims to provide a supernatant fluid instant granule which is prepared from a supernatant fluid extract and pharmaceutically acceptable auxiliary materials.
In one embodiment, the traditional Chinese medicine raw materials of the supernatant fluid extract comprise 1-3 parts of myrobalan, 4-6 parts of frangipani, 5-8 parts of mesona chinensis benth, 3-5 parts of fresh reed rhizome, 2-4 parts of pogostemon cablin and 1-4 parts of liquorice.
In one embodiment, the traditional Chinese medicine raw materials of the supernatant fluid extract comprise 1 part of myrobalan, 6 parts of frangipani, 7 parts of mesona chinensis benth, 4 parts of fresh reed rhizome, 4 parts of pogostemon cablin and 2 parts of liquorice.
In one embodiment, the supernatant beverage extract is prepared by the following method:
(1) weighing the traditional Chinese medicine raw materials according to the proportion, adding 9-12 times of water to soak for 2-4h, heating and decocting for 3-5h, decocting for 2-3 times, combining the decoction, cooling to room temperature, and filtering;
(2) adding 95% ethanol into the filtrate obtained in the step (1) until the ethanol concentration is 50% -60%, refrigerating, standing overnight, filtering, washing the obtained precipitate with ethanol for 2-3 times, mixing the washing solution with the obtained filtrate, and concentrating under reduced pressure to one fifth of the original volume to obtain a concentrated solution;
(3) purifying and refining the concentrated solution obtained in the step (2) by using a macroporous adsorption resin column, eluting by using 0%, 30%, 60% and 90% of ethanol respectively, recovering 30% and 60% of eluted parts, merging, concentrating under reduced pressure, and removing an ethanol solvent to obtain thick paste;
(4) and (4) freeze-drying the thick paste obtained in the step (3), and carrying out micronization treatment after drying to obtain freeze-dried powder of the supernatant fluid extract.
In one embodiment, in step (1) of the preparation method of the supernatant beverage extract, 10 times of water is added, the soaking time is 3 hours, the decoction time is 4 hours, and the decoction times are 3 times.
In one embodiment, the ethanol concentration finally reached in step (2) of the supernatant beverage extract preparation method is 50%, and the number of washing the precipitate is 3 times.
In one embodiment, the particle size range obtained after the micronization treatment in step (4) of the process for preparing the supernatant beverage extract is 150-250 μm.
In one embodiment, the excipients used to make the supernatant beverage instant granules are antioxidants, stabilizers, and sweeteners.
In one embodiment, the antioxidant is ascorbic acid.
In one embodiment, the stabilizing agent is selected from one or two of microcrystalline cellulose, sodium alginate, sodium carboxymethyl cellulose, maltodextrin or beta-cyclodextrin.
In one embodiment, the sweetener is selected from one or both of xylitol or aspartame.
In one embodiment, the stabilizer is a mixture of microcrystalline cellulose and beta-cyclodextrin in a 1: 2 ratio.
In one embodiment, the supernatant drink instant granules are made from 82% supernatant drink extract, 1% microcrystalline cellulose, 2% beta-cyclodextrin, 4% ascorbic acid, 5% xylitol, and 6% aspartame.
In one embodiment, the supernatant beverage instant granules are prepared into granules by wet granulation as is conventional in the art.
Another object of the present invention is to provide a method for preparing said supernatant beverage instant granules, comprising the steps of:
(1) weighing the traditional Chinese medicine raw materials according to the proportion, adding 9-12 times of water to soak for 2-4h, heating and decocting for 3-5h, decocting for 2-3 times, combining the decoction, cooling to room temperature, and filtering;
(2) adding 95% ethanol into the filtrate obtained in the step (1) until the ethanol concentration is 50% -60%, refrigerating, standing overnight, filtering, washing the obtained precipitate with ethanol for 2-3 times, mixing the washing solution with the obtained filtrate, and concentrating under reduced pressure to one fifth of the original volume to obtain a concentrated solution;
(3) purifying and refining the concentrated solution obtained in the step (2) by using a macroporous adsorption resin column, eluting by using 0%, 30%, 60% and 90% of ethanol respectively, recovering 30% and 60% of eluted parts, merging, concentrating under reduced pressure, and removing an ethanol solvent to obtain thick paste;
(4) freeze-drying the thick paste obtained in the step (3), and micronizing after drying to obtain freeze-dried powder of the supernatant fluid extract;
(5) and (4) adding pharmaceutically acceptable auxiliary materials into the freeze-dried powder obtained in the step (4), and preparing the freeze-dried powder into instant granules through a conventional wet granulation step.
The invention has the beneficial effects that: the invention purifies and refines the effective components of the supernatant fluid, and compared with the traditional decoction and low-sugar fluid beverage, the obtained supernatant fluid instant granules have better anti-inflammatory and health-care effects, and obviously improve the solubility, the brewing condition and the like. Has good taste, and is convenient for carrying, administration and storage.
Detailed Description
The invention may be further understood by reference to the following examples, which illustrate some methods of making or using. However, it is to be understood that these examples do not limit the present invention. Variations of the invention, now known or further developed, are considered to fall within the scope of the invention as described herein and claimed below.
Prescription optimization of supernatant drink instant granules-selection of stabilizer
The experiment inspects the influence of different stabilizers on the brewing condition of the supernatant beverage instant granules, selects ascorbic acid as an antioxidant, xylitol and aspartame as sweeteners, takes one or two of microcrystalline cellulose, sodium alginate, sodium carboxymethylcellulose, maltodextrin or beta-cyclodextrin as a stabilizer, prepares the stabilizer and the supernatant beverage extract freeze-dried powder into granules (the dosage of each raw material is the same), adds hot water at 80 ℃ for brewing, and observes the brewing condition.
TABLE 1 Effect of different stabilizers on the reconstitution of supernatant instant granules
And (4) conclusion: the preparation method comprises the following steps of (1) preparing microcrystalline cellulose: mixture of beta-cyclodextrin in a ratio of 1: 2 as stabilizer
The prepared instant granules are best after being mixed with hot water.
Example 1
(1) Weighing the traditional Chinese medicine raw materials according to 1 part of myrobalan, 6 parts of frangipani, 7 parts of mesona chinensis benth, 4 parts of fresh reed rhizome, 2 parts of pogostemon cablin and 2 parts of liquorice, adding 10 times of water to soak for 3 hours, heating and decocting for 4 hours, decocting for 3 times, combining decoction, cooling to room temperature, and filtering;
(2) adding 95% ethanol into the filtrate obtained in the step (1) until the ethanol concentration is 50%, refrigerating, standing overnight, filtering, washing the obtained precipitate with ethanol for 3 times, mixing the washing solution with the obtained filtrate, and concentrating under reduced pressure to one fifth of the original volume to obtain concentrated solution;
(3) purifying and refining the concentrated solution obtained in the step (2) by using a macroporous adsorption resin column, eluting by using 0%, 30%, 60% and 90% of ethanol respectively, recovering 30% and 60% of eluted parts, merging, concentrating under reduced pressure, and removing an ethanol solvent to obtain thick paste;
(4) freeze-drying the thick paste obtained in the step (3), and carrying out micronization treatment after drying to obtain the supernatant beverage extract freeze-dried powder with the particle size range of 200-;
(5) according to 82% of the freeze-dried powder obtained in the step (4), 1% of microcrystalline cellulose, 2% of beta-cyclodextrin, 4% of ascorbic acid, 5% of xylitol and 6% of aspartame, the instant granules are prepared by a conventional wet granulation step.
Example 2
(1) Weighing the traditional Chinese medicine raw materials according to 1 part of myrobalan, 6 parts of frangipani, 7 parts of mesona chinensis benth, 4 parts of fresh reed rhizome, 2 parts of pogostemon cablin and 2 parts of liquorice, adding 11 times of water to soak for 3.5h, heating and decocting for 3.5h, decocting for 3 times, combining decoction, cooling to room temperature, and filtering;
(2) adding 95% ethanol into the filtrate obtained in the step (1) until the ethanol concentration is 60%, refrigerating, standing overnight, filtering, washing the obtained precipitate with ethanol for 3 times, mixing the washing solution with the obtained filtrate, and concentrating under reduced pressure to one fifth of the original volume to obtain concentrated solution;
(3) purifying and refining the concentrated solution obtained in the step (2) by using a macroporous adsorption resin column, eluting by using 0%, 30%, 60% and 90% of ethanol respectively, recovering 30% and 60% of eluted parts, merging, concentrating under reduced pressure, and removing an ethanol solvent to obtain thick paste;
(4) freeze-drying the thick paste obtained in the step (3), and carrying out micronization treatment after drying to obtain the supernatant beverage extract freeze-dried powder with the particle size range of 200-;
(5) according to 79 percent of the freeze-dried powder obtained in the step (4), 1.5 percent of microcrystalline cellulose, 3 percent of beta-cyclodextrin, 4.5 percent of ascorbic acid, 6 percent of xylitol and 6 percent of aspartame, the instant granules are prepared by a conventional wet granulation step.
Example 3
(1) Weighing the traditional Chinese medicine raw materials according to 1 part of myrobalan, 6 parts of frangipani, 7 parts of mesona chinensis benth, 4 parts of fresh reed rhizome, 2 parts of pogostemon cablin and 2 parts of liquorice, adding 9 times of water to soak for 5 hours, heating and decocting for 5 hours, decocting for 3 times, combining decoction, cooling to room temperature, and filtering;
(2) adding 95% ethanol into the filtrate obtained in the step (1) until the ethanol concentration is 50%, refrigerating, standing overnight, filtering, washing the obtained precipitate with ethanol for 3 times, mixing the washing solution with the obtained filtrate, and concentrating under reduced pressure to one fifth of the original volume to obtain concentrated solution;
(3) purifying and refining the concentrated solution obtained in the step (2) by using a macroporous adsorption resin column, eluting by using 0%, 30%, 60% and 90% of ethanol respectively, recovering 30% and 60% of eluted parts, merging, concentrating under reduced pressure, and removing an ethanol solvent to obtain thick paste;
(4) freeze-drying the thick paste obtained in the step (3), and carrying out micronization treatment after drying to obtain the supernatant beverage extract freeze-dried powder with the particle size range of 200-;
(5) the preparation method comprises the following steps of (1) preparing a freeze-dried powder in the step (4), 2% of microcrystalline cellulose, 4% of beta-cyclodextrin, 5% of ascorbic acid, 7% of xylitol and 5% of aspartame into instant granules by a conventional wet granulation step.
Comparative example 1
Traditional supernatant drink: 1g of myrobalan, 6g of frangipani, 7g of mesona chinensis benth, 4g of fresh reed rhizome, 2g of pogostemon cablin and 2g of liquorice, wherein 1000mL of water is decocted, and the amount of the decoction is 310mL per pot: 310 ml/day.
Comparative example 2
A low-sugar concentrate: 40g of myrobalan, 240g of frangipani, 280g of mesona blume, 160g of fresh reed rhizome, 80g of patchouli, 80g of liquorice, sugar (80 g of xylitol, 120g of cane sugar, 1.8g of citric acid and 1g of xanthan gum) and preservative (0.05 percent of nipagin ethyl vinegar and 0.25 percent of benzoic acid are dissolved in 20ml of 75 percent alcohol) to prepare 1000ml of the concentrated low-sugar heat-clearing health-care drink.
Comparative Effect example-anti-inflammatory Effect
First, granuloma experiment of cotton ball
1. Purpose of study
Through a rat cotton ball granuloma experiment, the granuloma weight is weighed, and the anti-inflammatory effect of supernatant fluid of different formulations is compared.
2. Experimental methods
SD rats were randomly divided into 6 groups of 6 rats each. The normal group, the model group, the dexamethasone-positive group, the comparative example 1 high-dose group, the comparative example 1 low-dose group, the comparative example 2 high-dose group, the comparative example 2 low-dose group, the example 1 high-dose group, and the example 1 low-dose group, respectively. The positive medicine group adopts dexamethasone sodium phosphate which is injected into the abdominal cavity, and the normal group and the model group and the administration group are continuously administered for 30 days by intragastric administration with the same volume.
And 8 days before the experiment is finished, preparing 23mg of compact cotton balls from the absorbent cotton, placing the cotton balls in a constant-temperature drying oven for drying at 60 ℃ for 3h after autoclaving, taking out the cotton balls, drying and storing the cotton balls for later use. A rat was anesthetized with 3mL/kg of 10% chloral hydrate, the hair of the groin on the right side of the rat was removed, iodophor was sterilized, 75% ethanol was deiodinated, the skin was cut, a cotton ball (autoclaved and dried, 23mg) was implanted, the incision was closed, and iodophor was sterilized. On the day of experiment, after giving the test object for 1 hour, the rats were sacrificed by a large dose of chloral hydrate, the skin was cut at the original sutured place, the cotton ball granulation tissue was peeled and taken out, placed in a weighed clean plate, and weighed after being uncapped and dried for 1 hour in a constant temperature drying oven at 60 ℃, and the net amount of granuloma was calculated.
The net granuloma (mg) is the weight of granuloma of cotton ball after drying-weight of raw cotton ball
4. Statistical treatment
All data are expressed as mean ± Standard Deviation (SD) and the data were subjected to T-test using Graphpad Prism 6, with P < 0.05 being statistically significant.
5. Results of the experiment
As shown in Table 2, comparative example 1, comparative example 2 and example 1 all reduced rat cotton ball granuloma to some extent, and the anti-inflammatory effect of example 1 was significantly better than that of comparative example 1 and comparative example 2.
TABLE 2 Net amount of granuloma in rat (mg)
Note that ＊ P was < 0.05 compared to model group, ＊＊ P was < 0.01 compared to model group, ＊＊＊ P was < 0.001 compared to model group, and compared to comparative example 1,#p is less than 0.01; in comparison with the comparative example 2,&P＜0.01。
swelling of toes and toes
1. Purpose of study
The toe volume of rats in different time periods is measured, and the anti-inflammatory effect of supernatant fluid of different dosage forms is compared.
2. Experimental Material
2.2 Experimental animals
SPF SD rats (56-63 days, 170-190 g) were purchased from Guangdong province medical laboratory animal center with license number SCXK (Guangdong) 2013-.
A breeding environment: the temperature is 23 +/-2 ℃, and the illumination time is 12h/d (7: 00-19: 00).
2.3 devices and reagents
Picric acid, chloral hydrate, iodine tincture, normal saline, 75% sterile alcohol, an intragastric injection needle, a cotton swab, a suture needle and thread, a needle holder, a pair of tweezers, scissors, an injector and an autoclave.
3. Experimental methods
Animal groups and administration were as above.
Dextran 4 million was made up to 1% concentration with sterile distilled water on the day of experiment completion for future use. After 1 hour of administration, the volume of the right hind toe of each group of rats was measured by toe volume measuring instrument as 0 hour toe volume. Then, 4 thousands of 0.1mL of 1% dextran was subcutaneously injected into the right hind toe of the rat, and the volume of the toe of the rat was measured at 1, 2, 4, and 6 hours, respectively, and the same site was measured 3 times to obtain an average value. And calculating the toe swelling rate of each time period by taking the difference between the toe volume measured at different time periods and the toe volume before the action of the inflammatory agent as a swelling value.
Swelling rate (%). swelling value/volume of pro-inflammatory toes × 100%
4. Statistical treatment
All data are expressed as mean ± Standard Deviation (SD) and the data were subjected to T-test using Graphpad Prism 6, with P < 0.05 being statistically significant.
5. Results of the experiment
As shown in Table 3, comparative example 1, comparative example 2 and example 1 all had the effect of reducing the tissue swelling of rats, and the anti-inflammatory effect of example 1 was significantly superior to that of comparative example 1 and comparative example 2.
TABLE 3 toe swelling Rate (%) of rats at different time periods
Note that ＊ P was < 0.05 compared to model group, ＊＊ P was < 0.01 compared to model group, ＊＊＊ P was < 0.001 compared to model group, and compared to comparative example 1,#p is less than 0.01; in comparison with the comparative example 2,&P＜0.01。
third, auricle swelling test
1. Purpose of study
The anti-inflammatory effect of the supernatant fluid of different dosage forms is examined by weighing the tab and comparing the swelling rate of the auricle of the mice of the administration group and the model group.
2. Experimental Material
2.2 Experimental animals
SPF-grade KM mice (25-35 days, 18-22 g) were purchased from Guangdong province medical laboratory animal center with license number SCXK (Guangdong) 2013-.
A breeding environment: the temperature is 23 +/-2 ℃, and the illumination time is 12h/d (7: 00-19: 00).
2.3 devices and reagents
Picric acid, dimethylbenzene, normal saline, a gastric lavage needle, a lug puncher and an injector.
3. Experimental methods
Kunming mice were randomly divided into 6 groups of 8 mice each. The normal group, the model group, the dexamethasone-positive group, the comparative example 1 high-dose group, the comparative example 1 low-dose group, the comparative example 2 high-dose group, the comparative example 2 low-dose group, the example 1 high-dose group, and the example 1 low-dose group, respectively. The positive medicine group adopts dexamethasone sodium phosphate which is injected into the abdominal cavity, and the normal group and the model group and the administration group are continuously administered for 30 days by intragastric administration with the same volume.
60 minutes after the last dose, 20 microliters of xylene were drawn up and dropped into the center of the auricle on the lateral side of the mouse's right ear, allowing free diffusion, and the left ear was not used as a control. After 30 minutes, the mice were sacrificed by removing the cervical vertebrae, both ears were cut off, the ears were punched out at the same positions of both ears by a 9mm diameter punch and weighed, and the auricle swelling rate was calculated by taking the difference between the weights of both ears as the auricle swelling value.
Auricle swelling rate (%) -. auricle swelling value/control ear weight × 100%
4. Statistical treatment
All data are expressed as mean ± Standard Deviation (SD) and the data were subjected to T-test using Graphpad Prism 6, with P < 0.05 being statistically significant.
5. Results of the experiment
As shown in table 4, comparative example 1, comparative example 2 and example 1 all reduced the rate of auricle swelling in mice caused by xylene, and the anti-inflammatory effect of example 1 was significantly superior to that of comparative example 1 and comparative example 2.
TABLE 4 mouse auricular swelling Rate (%)
Note that ＊ P was < 0.05 for the model group, ＊＊ P was < 0.01 for the model group, ＊＊＊ P was < 0.001 for the model group, and compared to dosage form 1,#p is less than 0.01; in comparison with the comparative example 2,&P＜0.01。
fourth, conclusion
In three experiments of rat cotton ball granuloma, rat tissue swelling and mouse auricle swelling, the comparative example 1, the comparative example 2 and the example 1 have better anti-inflammatory effects, and the anti-inflammatory effect of the example 1 is obviously better than that of the comparative example 1 and the comparative example 2.
This summary merely illustrates some embodiments which are claimed, wherein one or more of the features recited in the claims can be combined with any one or more of the embodiments, and such combined embodiments are also within the scope of the present disclosure as if they were specifically recited in the disclosure.
Claims (1)
1. The supernatant drink instant granules are characterized by being prepared from 82% of a supernatant drink extract, 1% of microcrystalline cellulose, 2% of beta-cyclodextrin, 4% of ascorbic acid, 5% of xylitol and 6% of aspartame, wherein the traditional Chinese medicine raw materials of the supernatant drink extract comprise 1 part of myrobalan, 6 parts of frangipani, 7 parts of mesona chinensis benth, 4 parts of fresh reed rhizome, 2 parts of pogostemon cablin and 2 parts of liquorice;
the preparation method of the supernatant drink instant granules comprises the following steps:
(1) weighing the traditional Chinese medicine raw materials according to the proportion, adding 10 times of water to soak for 3h, heating and decocting for 4h, decocting for 3 times, combining the decoction, cooling to room temperature, and filtering;
(2) adding 95% ethanol into the filtrate obtained in the step (1) until the ethanol concentration is 50%, refrigerating, standing overnight, filtering, washing the obtained precipitate with ethanol for 3 times, mixing the washing solution with the obtained filtrate, and concentrating under reduced pressure to one fifth of the original volume to obtain concentrated solution;
(3) purifying and refining the concentrated solution obtained in the step (2) by using a macroporous adsorption resin column, eluting by using 0%, 30%, 60% and 90% of ethanol respectively, recovering 30% and 60% of eluted parts, merging, concentrating under reduced pressure, and removing an ethanol solvent to obtain thick paste;
(4) freeze-drying the thick paste obtained in the step (3), and carrying out micronization treatment after drying to obtain the supernatant beverage extract freeze-dried powder with the particle size range of 200-;
(5) and (3) preparing instant granules by wet granulation according to the proportion of 82% of the freeze-dried powder obtained in the step (4), 1% of microcrystalline cellulose, 2% of beta-cyclodextrin, 4% of ascorbic acid, 5% of xylitol and 6% of aspartame.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611149253.0A CN106605818B (en) | 2016-12-13 | 2016-12-13 | Instant granule of Shangqingyin and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611149253.0A CN106605818B (en) | 2016-12-13 | 2016-12-13 | Instant granule of Shangqingyin and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106605818A CN106605818A (en) | 2017-05-03 |
| CN106605818B true CN106605818B (en) | 2020-01-17 |
Family
ID=58636143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611149253.0A Active CN106605818B (en) | 2016-12-13 | 2016-12-13 | Instant granule of Shangqingyin and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106605818B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115887525B (en) * | 2022-11-25 | 2024-06-18 | 国药集团同济堂（贵州）制药有限公司 | Preparation method, detection method and characteristic map construction method of agastache rugosa extract |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101999493B (en) * | 2010-12-08 | 2013-07-31 | 费维来 | Preparation method of plant health-care cool tea |
| CN102845569A (en) * | 2012-04-01 | 2013-01-02 | 哈尔滨珍宝制药有限公司 | Herbal tea and preparation method thereof |
| CN102935110B (en) * | 2012-11-02 | 2014-08-06 | 青岛蔚蓝生物股份有限公司 | Coated granules containing natural oregano oil for birds and preparation method thereof |
| CN104248035A (en) * | 2014-02-14 | 2014-12-31 | 亳州市益寿轩药膳食品有限公司 | Men's Maca health care solid beverage formula and preparation method |
| CN104256840A (en) * | 2014-09-01 | 2015-01-07 | 姚晓谊 | Health solid beverage formula and preparation method of health solid beverage |
| CN104365914A (en) * | 2014-11-20 | 2015-02-25 | 广西中医药大学 | Solid herbal tea with heat-clearing, detoxifying, internal heat-removing and body fluid secretion-promoting effects and preparation method thereof |
-
2016
- 2016-12-13 CN CN201611149253.0A patent/CN106605818B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106605818A (en) | 2017-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103893722B (en) | A kind of Chinese medicine composition and its preparation method treating sunburn | |
| KR20080105825A (en) | Herb composition useful for arthritis treatment or prevention and preparation thereof | |
| CN104815192A (en) | Pharmaceutical composition for treating hypertension and application of pharmaceutical composition | |
| CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
| CN106605818B (en) | Instant granule of Shangqingyin and its preparation method | |
| CN104398969B (en) | A kind of Post kidney transplantation treatment and health Chinese medicine | |
| CN103845678B (en) | A kind of pharmaceutical composition for treating infant's dermatitis | |
| CN103356802B (en) | Medicament for treating mastitis, and preparation method thereof | |
| CN104431061A (en) | Tea with functions of reducing blood sugar and losing weight and production method thereof | |
| CN100425169C (en) | Chinese herbal health-caring beverage | |
| CN108125237B (en) | Health product for relieving cough, eliminating phlegm and resisting inflammation and preparation process thereof | |
| CN102940762B (en) | Traditional Chinese medicine for treating gouty arthritis | |
| CN105770074A (en) | Traditional Chinese medicine composition for treating wind-heat common cold and preparation method thereof | |
| CN105125706A (en) | Dandelion-containing traditional Chinese medicinal composition with functions of clearing away heat and toxic materials, relieving sore-throat and eliminating phlegm and preparation method | |
| CN100431584C (en) | Chinese medicinal formulation for caring and enlarging breast | |
| KR20060029807A (en) | A herb medicine composite for treating dermatitis and a manufacturing process of it | |
| CN103446564A (en) | Traditional Chinese medicine composition for antisepsis and antiinflammation and preparation method thereof | |
| CN116059301B (en) | Tea drink for preventing influenza and preparation method thereof | |
| CN108714167B (en) | A Chinese medicinal preparation for external use for treating vitiligo, and its preparation method | |
| CN105709086A (en) | Throat clearing tea bag and preparation method thereof | |
| CN108030855B (en) | Traditional Chinese medicine composition for treating cerebral arterial thrombosis and preparation method thereof | |
| CN105362784A (en) | Medicine composition for treating hysteromyoma and preparation method thereof | |
| CN105362993A (en) | Tincture for treating ichthyophthiriasis of parrotfish and preparation method of tincture for treating ichthyophthiriasis of parrotfish | |
| CN105561007A (en) | Traditional Chinese medicine preparation for treating infantile influenza and preparation method | |
| CN104398902A (en) | Deficiency-cold type chronic bronchitis treating preparation for clearing away heat and dispersing lung and preparation method of preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220419 Address after: 519000 Room 302, building 5, No. 100, Feipeng Road, Guangdong Macao cooperative traditional Chinese medicine science and Technology Industrial Park, Hengqin new area, Zhuhai City, Guangdong Province Patentee after: Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co.,Ltd. Address before: 510000 Whampoa Avenue, Guangzhou, Guangzhou, Guangdong Province, No. 601 Patentee before: Jinan University |